Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2026-06-24 18:06:17 ET · period of report 2026-06-22 · accession 0001470831-26-000634 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-24 18:06 | 2026-06-22 | BBIO | Lo Andrew | Dir | A - Grant | $0.00 | +3,990 | 18.1K | +28% | $0 |
| D | 2026-06-24 18:06 | 2026-06-22 | BBIO | Lo Andrew | Dir | A - Grant | $0.00 | +5,277 | 5,277 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-22 | A | A | 3,990 | $0.00 | 18,079 | D | — | — | (F1) Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. (F2) Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-06-22 | A | A | 5,277 | $0.00 | 5,277 | D | $68.92 · — to 2036-06-21 | 5,277 Common Stock | (F3) The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |